 |
|
ACRUS broadens contraceptive spray strategy
August 11, 2006Acrux (ASX: ACR), the Australian company with patient-preferred technology for delivering drugs across the skin, today announced that it has reached agreement with Population Council, Inc., to amend the Licence Agreement signed in February 2006.
Under the Licence Agreement, Acrux is developing a contraceptive spray, combining Acrux's patented MDTS® spray delivery technology with Population Council's new generation contraceptive Nestorone®. Established in 1952 and headquartered in New York, Population Council has a proven track record in the successful development of female contraceptive products.
Under the terms of the amendment, Acrux is no longer restricted to developing and commercialising only contraceptive sprays containing Nestorone®. All other material terms of the Licence Agreement remain unchanged.
"This amendment has paved the way for Acrux to apply MDTS® to a far wider range of contraceptive hormones, which in turn makes our technology more attractive to potential global partners," said Richard Treagus, Acrux CEO.
Following the successful completion of Phase 1 clinical trials with Nestorone® MDTS, Acrux has moved quickly to start formulation development of additional contraceptive spray products.
"The global market for hormonal contraceptives approximates US$6.5 billion per annum. With the MDTS® technology applicable to a range of contraceptive hormones, it was important to ensure that we were in the strongest possible position to fully exploit the value of our technology in this market", Treagus added.
MDTS® has a number of advantages over existing methods of contraceptive delivery systems, such as pills and patches. At launch, the contraceptive MDTS® will be the first transdermal contraceptive spray in the market, and it has the potential to become the contraceptive of choice for many women.
Research Australia
"This amendment has paved the way for Acrux to apply MDTS® to a far wider range of contraceptive hormones, which in turn makes our technology more attractive to potential global partners," said Richard Treagus, Acrux CEO.
Following the successful completion of Phase 1 clinical trials with Nestorone® MDTS, Acrux has moved quickly to start formulation development of additional contraceptive spray products.
"The global market for hormonal contraceptives approximates US$6.5 billion per annum. With the MDTS® technology applicable to a range of contraceptive hormones, it was important to ensure that we were in the strongest possible position to fully exploit the value of our technology in this market", Treagus added.
MDTS® has a number of advantages over existing methods of contraceptive delivery systems, such as pills and patches. At launch, the contraceptive MDTS® will be the first transdermal contraceptive spray in the market, and it has the potential to become the contraceptive of choice for many women.
Research Australia
Contraceptive Current Events and Contraceptive News RSSEnjoying school key to tackling teenage pregnancy
Youth development programmes that tackle deprivation and help children and young people enjoy school are successful in reducing teenage pregnancy rates.
Workplace BPA exposure increases risk of male sexual dysfunction
High levels of workplace exposure to Bisphenol-A may increase the risk of reduced sexual function in men, according to a Kaiser Permanente study appearing in the journal Human Reproduction, published by Oxford Journals.
For gay and straight men, facial attraction operates similarly
A new study from a researcher at Harvard University finds that gay men are most attracted to the most masculine-faced men, while straight men prefer the most feminine-faced women.
The IUD is the most popular long-acting contraceptive amongst Europeans
A European study has defined the profile for the usage of long-acting contraceptive methods. The work, presented with the National Congress of Gynaecology award, shows, amongst other things, that 10% of women use these methods, the majority over 30 years old.
Research: Migraine and cardiovascular disease: Systematic review and meta-analysis
Migraine with aura (temporary visual or sensory disturbances before or during a migraine headache) is associated with a twofold increased risk of stroke, finds a study published on bmj.com today.
An HIV-blocking gel for women
University of Utah scientists developed a new kind of "molecular condom" to protect women from AIDS in Africa and other impoverished areas. Before sex, women would insert a vaginal gel that turns semisolid in the presence of semen, trapping AIDS virus particles in a microscopic mesh so they can't infect vaginal cells.
UTMB study identifies women at risk of gaining excessive weight with injectable birth control
Researchers at the University of Texas Medical Branch at Galveston have identified women who are likely to gain weight while using depot medroxyprogesterone acetate, more commonly known as Depo-Provera or the birth control shot.
Study explains potential failure of oral contraceptives with obese women
Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.
2 reproductive factors are important predictors of death from ovarian cancer
Researchers from the Centers for Disease Control and Prevention (CDC) found that survival among women with ovarian cancer is influenced by age of menarche and total number of lifetime ovulatory cycles.
Teens are heading in wrong direction: Likely to have sex, but not use contraception
Between 2003 and 2007, the progress made in the 1990s and early 2000s in improving teen contraceptive use and reducing teen pregnancy and childbearing stalled, and may even have reversed among certain groups of teens.
More Contraceptive Current Events and Contraceptive News Articles
 |
Ortho options vaginal contraceptive gel with applicators, unscented - 10 by J&J HEALTH CARE. INDICATIONS: Ortho options vaginal contraceptive gel with applicators, unscented is used for the prevention of pregnancy. Apply not more than an hour before intercourse. For best protection against pregnancy. |
 |
Contraceptive Technology, 19th Edition by Robert A. Hatcher (Author), James Trussell (Author), Anita L. Nelson (Author), Willard Cates Jr. (Author), Felicia Stewart (Author) New scientific and medical developments in reproductive health have emerged in the past 5 years. This latest edition of Contraceptive Technology focuses on the benefits of a variety of safe and effective contraceptive methods, enabling physicians to counsel their patients on some of the most important decisions that will shape their lives. Edited for ob/gyns, reproductive medicine MDs, gynecologists and primary care physicians specializing in women's health, the 19th edition of Contraceptive Technology continues to provide recommendations that will ensure that every pregnancy is intended and as safe as possible.
This edition refers to the soft cover version of this title. |
 |
Vaginal Contraceptive Film - 28% Nonoxynol-9: 12 units. by VCF VCF Vaginal Contraceptive Film is a translucent 2 inch by 2 inch insert Begins to dissolve instantly No hormonal side effects Kills sperm on contact Sexually enhancing Lasts up to 3 hours Contains the spermicide doctors recommend most, Nonoxynol-9 NOTE: this product is hand packed VCF is a translucent square of material containing the active ingredient Nonoxynol-9, a wisely used, highly efficient spermicide. Placed high in the vagina, as close as possible to the neck of the womb (cervix), it dissolves into a gel which exerts a powerful contraceptive effect against sperm. It is a potent spermicidal agent used successfully by millions of women. Because VCF is small and unnoticed in use, it can be used discreetly by the woman. It does not run and will not stain. VCF is eventually washed... |
 |
i-pill Emergency Contraceptive Pill by Cipla |
|
Managing Contraceptive Pill Patients by Richard P. Dickey (Author) Louisiana State Univ., New Orleans. Contains most of the known oral contraceptive (OC) side effects and their causes with a recommended plan of management. Tables list categorical activities of OCs. Intended to help clinicians choose among OC types. Trim size: 7.5 x 4.25 inches. Softcover. | |
 |
New & Improved TODAY Sponge Vaginal Contraceptive (TEAL BLUE BOX) Sponge 3 Pack EXP FEB 2011 by Mayer Laboratories, INc. Today Sponge is a soft polyurethane foam sponge containing nonoxynol 9, a spermicide used by millions of women for more that 20 years in other forms of intravaginal drug products. Today Sponge has a unique 3-way action which provides safe and effective protection without hormones. From the makers of Kimono CONDOMS. |
 |
Vaginal Contraceptive Inserts by Encare Encare vaginal contraceptive inserts are the birth control women can trust! Encare Vaginal Contraceptive Inserts for the prevention of pregnancy No hormonal side effects Kills sperm on contact and dispenses a physical barrier of protection against the cervix Individually wrapped Convenient to carry Contains the spermicide doctors recommend most, Nonoxynol-9 *This product is not effective against HIV, AIDS, or other sexually transmitted diseases. |
 |
Devices and Desires: A History of Contraceptives in America by Andrea Tone (Author) From thriving black market to big business, the commercialization of birth control in the United States In Devices and Desires, Andrea Tone breaks new ground by showing what it was really like to buy, produce, and use contraceptives during a century of profound social and technological change. A down-and-out sausage-casing worker by day who turned surplus animal intestines into a million-dollar condom enterprise at night; inventors who fashioned cervical caps out of watch springs; and a mother of six who kissed photographs of the inventor of the Pill -- these are just a few of the individuals who make up this riveting story. |
 |
Vaginal Contraceptive Foam - 12.5% by VCF VCF Vaginal Contraceptive Foam is a white, lightly scented, non-staining foam Laboratory tested contraceptive works instantly Applicator included Net Wt. 0.6 oz. VCF Vaginal Contraceptive Foam is a white, lightly scented, non-staining foam. VCF is tested by independent laboratories for determination of sperm inactivating qualities, using the I.P.P.F. agreed protocol. VCF foam is effective immediately, and is easy to use. VCF contains the spermicide most recommended by doctors, nonoxynol-9. *This product is not effective against HIV, AIDS, or other sexually transmitted diseases. |
 |
Vcf Vaginal Contraceptive Film - 9 sku 1293547 by APOTHECUS INC. |
| © 2009 BrightSurf.com |